Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Chugai Foresees Tepid Growth for Next 3 Years: New Biz Plan
Chugai Pharmaceutical predicts only a low-single-digit compound annual growth rate not exceeding the 3% range for the next three years on a core EPS basis, according to its 2016-2018 business plan unveiled on January 28. “It will be difficult to…
To read the full story
Related Article
- Chugai Positions Mid-Sized Molecule Drugs as Third Pillar of Business, Aims to Produce First Candidate within 3 Years
February 1, 2016
- Kadcyla Development for Gastric Cancer Discontinued: Chugai
January 29, 2016
- Chugai Delivers Record Earnings, but Pegasys Falters on IFN-Free Hep C Therapies
January 29, 2016
BUSINESS
- Sanofi Eyes Double-Digit Annual Growth for Japan Vaccine Business: Exec
May 20, 2026
- Takeda Hit with Massive Damages Verdict in US Amitiza Antitrust Case
May 20, 2026
- Bayer Files FXIa Inhibitor Asundexian in Japan
May 20, 2026
- Japan’s Big 4 Drug Wholesalers See Profit Pressure Intensify in FY2025
May 19, 2026
- Asahi Kasei Starts Japan PIII of Extended Teribone Dosing
May 19, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…